Advanced search
Publication Cover
OncoTargets and Therapy Volume 13, 2020 - Issue
Submit an article Journal homepage
86
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling

Xiaomin Cai1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China
,
Bin Wei1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China;2 Department of Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai’an223300, People's Republic of China
,
Lele Li1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China
,
Xiaofeng Chen1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-6137-5234
ORCID Icon,
Jing Yang1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China
,
Xiaofei Li1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China
,
Xiaozheng Jiang1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China
,
Mu Lv1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China
,
Mingyang Li1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China
,
Yumeng Lin3 State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, People’s Republic of China
,
Qiang Xu3 State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, People’s Republic of China
,
Wenjie Guo3 State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8506-3905
ORCID Icon &
Yanhong Gu1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 11031-11044 | Published online: 29 Oct 2020

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.